Frontline Combo Therapy Shows Improved Results for Ovarian Cancer Treatment
Frontline maintenance therapy with the combination of olaparib (Lynparza) and bevacizumab (Avastin) improved median progression-free survival (PFS) by 5.5 months compared with bevacizumab and placebo for patients with newly diagnosed, advanced ovarian cancer following prior treatment with a platinum-based chemotherapy plus bevacizumab, according findings from the phase III PAOLA-1 trial presented at the ESMO Congress 2019.1
The median PFS in the olaparib arm was 22.1 months compared with 16.6 months in the placebo arm, representing a 41% reduction in the risk of progression or death with the addition of the PARP inhibitor (HR, 0.59; 95% CI, 0.49-0.72; P <.0001). This benefit was observed across all patient subsets but was more pronounced for those with tumors testing positive for BRCA1/2 mutations (tBRCAm) and for those with a homologous recombination deficiency (HRD) score of ≥42 by the myChoice HRD Plus assay (HRD-positive).
Read more from Oncology Nursing News, by SILAS INMAN, Frontline Combo Therapy Shows Improved Results for Ovarian Cancer Treatment